Other names: OCIM HGNC (Hugo): MYEOV Location: 11q13 Local order: 350 kb centromeric of cyclin D1. Note: Detected by application of the NIH/3T3 tumorigenicity assay. However MYEOV cDNA was not positive in NIH/3T3 assay.
DNA/RNA
Description 2 exons; 3.5 kb transcript represents unspliced mRNA.
Transcription
Main transcript 2.8 kb (broad band because of alternative splice products); minor transcript 3.5 kb; coding sequence 313 or 255 amino acids. In normal tissues hardly any expression detectable. High expression in a subset of multiple myeloma cell lines with a t(11;14)(q13;q32) and in breast tumors and esophageal squamous cell carcinomas with or without 11q13 amplification.
Protein
Description 313 or 255 amino acids; contains one RNP-1 motif and 6 regions that might function as a transmembrane domain. Leucine-rich stretch at C-terminal.
Expression

5' UTR inhibits efficient translation of the protein
Localisation
In endoplasmic reticulum and mitochondria.
Implicated in t(11;14)(q13;q32)
Disease Subset of multiple myeloma cell lines with t(11;14)(q13;q32). Cytogenetics Myeov overexpression due to juxtaposition to the 5' enhancer or the most telomeric 3' enhancer of the immunoglobulin heavy chain (IgH).
11q13 amplification and/or overexpression
Disease Breast cancer; esophageal squamous cell carcinomas. Prognosis MYEOV DNA amplification correlated with estrogen and progesterone receptor-positive cancer, invasive lobular carcinoma type and axillary nodal involvement. In contrast to cyclin D1 amplification, no association with disease outcome could be found.
